Press releases
Find out more about Ferring latest announcements.
Press releases
-
Frontiers in Microbiology Publishes Article Detailing Novel Microbiome-based Biomarker of Post-Antibiotic Disruptions in Gut Microbiota
-Ferring’s Microbiome Health Index™ is a promising tool that measures disrupted gut microbiota after antibiotic treatment, subsequent gut microbiota restoration, and the potential clinical impact of microbiome-based live biotherapeutics Parsippany, NJ, USA – January 7, 2022 – Ferring Pharmaceuticals and Rebiotix, a Ferring Company, today announced a publication detailing the development and validation of their first-of-its-kind prototype biomarker, designed to […]
-
Ferring Pharmaceuticals Supports the Proclamation of November as Clostridioides difficile Infection Awareness Month in New Jersey and Minnesota
-In conjunction with C. Diff Infection Awareness Month, Ferring Pharmaceuticals launches new educational website Parsippany, New Jersey – November 11, 2021 – Ferring Pharmaceuticals and Rebiotix Inc., a Ferring Company, appreciate the support of New Jersey and Minnesota for officially recognizing November as Clostridioides difficile (C. diff) Infection Awareness Month for the second year in a row. The proclamations from […]
-
Ferring Presents Award-Winning, Real-World Outcomes Analysis for Investigational Microbiota-Based Live Biotherapeutic, RBX2660, at ACG 2021
-New retrospective analysis found RBX2660 demonstrated efficacy and safety outcomes among a real-world population of C. difficile (CDI) patients, including those with comorbidities previously excluded from clinical trials Analysis adds to the consistent body of efficacy and safety evidence for RBX2660 across prospective and retrospective analyses and varying patient populations Parsippany, NJ, USA – October 25, 2021 – Ferring Pharmaceuticals and […]